Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic;Diabetes und kardiovaskuläre Erkrankung: Pathophysiologie einer lebensbedrohlichen Epidemie

Herz

Volumn 41, Issue 3, 2016, Pages 184-192

  King, R J ^a   Grant, P J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Atherothrombosis; Cardiovascular disease; Diabetes; Hyperglycaemia; Pathophysiology

Indexed keywords

ALOGLIPTIN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; EMPAGLIFLOZIN; FIBRINOGEN; GLICLAZIDE; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; INTERLEUKIN 6; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SITAGLIPTIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE PREDISPOSITION; FIBRINOLYSIS; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MEDIUM TERM GLYCEMIC CONTROL; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT TERM GLYCEMIC CONTROL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOSIS; CAUSALITY; EVIDENCE BASED MEDICINE; INTERNATIONAL COOPERATION; MORTALITY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ATHEROSCLEROSIS; CAUSALITY; DIABETES MELLITUS; EVIDENCE-BASED MEDICINE; HUMANS; INTERNATIONALITY; RISK FACTORS; SURVIVAL RATE; THROMBOSIS; TREATMENT OUTCOME;

EID: 84962294346     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-016-4414-8     Document Type: Article

References (77)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234
2. Cubbon RM, Wheatcroft SB, Grant PJ et al (2007) Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J 28:540–545
3. Kahn MB, Cubbon RM, Mercer B et al (2012) Association of diabetes with increased all-cause mortality following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in the contemporary era. Diabetes Vasc Dis Res 9:3–9
4. Anonymous (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977–986
5. Anonymous (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853
6. Semple RK, Savage DB, Cochran EK, Gorden P, O’Rahilly S (2011) Genetic syndromes of severe insulin resistance. Endocr Rev 32:498–514
7. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97:2601–2610
8. Perticone F, Ceravolo R, Candigliota M et al (2001) Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 50:159–165
9. Kohler HP, Grant PJ (2000) Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease. N Engl J Med 342:1792–1801
10. Festa A, D’Agostino R Jr., Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131–1137
11. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie, Szklo M (1991) Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 91:191–205
12. Heywood DM, Mansfield MW, Grant PJ (1996) Factor VII gene polymorphisms, factor VII:C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus. Thromb Haemost 75:401–406
13. Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F (2005) Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54:570–575
14. Thorand B, Lowel H, Schneider A et al (2003) C‑reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICa Augsburg cohort study, 1984–1998. Arch Intern Med 163:93–99
15. Balletshofer BM, Rittig K, Enderle MD et al (2000) Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101:1780–1784
16. Mansfield MW, Heywood DM, Grant PJ (1996) Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 94:2171–2176
17. Mansfield MW, Stickland MH, Grant PJ (1997) PAI-1 concentrations in first-degree relatives of patients with non-insulin-dependent diabetes: metabolic and genetic associations. Thromb Haemost 77:357–361
18. Naseem KM (2005) The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 26:33–65
19. Tanner FC, Meier P, Greutert H, Champion C, Nabel EG, Luscher TF (2000) Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation 101:1982–1989
20. Bohl KS, West JL (2000) Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation. Biomaterials 21:2273–2278
21. Clapp BR, Hingorani AD, Kharbanda RK et al (2004) Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res 64:172–178
22. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon ROIII (1995) Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 92:320–326
23. Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA (2003) Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 89:993–997
24. Levi M, van der Poll T (2010) Inflammation and coagulation. Crit Care Med 38:S26–S34
25. Cirillo P, Golino P, Calabro P et al (2005) C‑reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 68:47–55
26. Singh U, Jialal I (2006) Oxidative stress and atherosclerosis. Pathophysiology 13:129–142
27. Taylor AA (2001) Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. Endocrinol Metab Clin North Am 30:983–997
28. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820
29. Robertson RP, Harmon JS (2006) Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 41:177–184
30. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121:2111–2117
31. Goossens GH (2008) The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 94:206–218
32. Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C‑reactive protein on human endothelial cells. Circulation 102:2165–2168
33. Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444:875–880
34. Torimoto K, Okada Y, Mori H, Tanaka Y (2013) Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol 12:1
35. Okada K, Hibi K, Gohbara M et al (2015) Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes. Cardiovasc Diabetol 14:111
36. Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687
37. Gerrits AJ, Koekman CA, van Haeften TW, Akkerman JW (2010) Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin. Diabetes 59:1487–1495
38. Grant PJ (2007) Diabetes mellitus as a prothrombotic condition. J Intern Med 262:157–172
39. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS (1997) Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 46(Suppl 2):9–13
40. Undas A, Wiek I, Stepien E, Zmudka K, Tracz W (2008) Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care 31:1590–1595
41. Dunn EJ, Ariens RA (2004) Fibrinogen and fibrin clot structure in diabetes. Herz 29:470–479
42. Ajjan R, Grant PJ (2006) Coagulation and atherothrombotic disease. Atherosclerosis 186:240–259
43. Pieters M, van Zyl DG, Rheeder P et al (2007) Glycation of fibrinogen in uncontrolled diabetic patients and the effects of glycaemic control on fibrinogen glycation. Thromb Res 120:439–446
44. Hess K, Alzahrani SH, Mathai M et al (2011) A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 55(4):1103–1113
45. Dunn EJ, Ariens RA, Grant PJ (2005) The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48:1198–1206
46. Dunn EJ, Philippou H, Ariens RA, Grant PJ (2006) Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49:1071–1080
47. Jorneskog G, Egberg N, Fagrell B et al (1996) Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 39:1519–1523
48. Pieters M, Covic N, van der Westhuizen FH et al (2008) Glycaemic control improves fibrin network characteristics in type 2 diabetes – a purified fibrinogen model. Thromb Haemost 99:691–700
49. Seljeflot I, Larsen JR, Dahlgren S, Hanssen KF, Arnesen H (2006) Fibrinolytic activity is highly influenced by long-term glycemic control in Type 1 diabetic patients. J Thromb Haemost 4:686–688
50. Ajjan RA, Gamlen T, Standeven KF et al (2013) Diabetes is associated with post-translational modifications in plasminogen resulting in reduced plasmin generation and enzyme specific activity. Blood 122(1):134–142
51. Agren A, Jorneskog G, Elgue G, Henriksson P, Wallen H, Wiman B (2014) Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes Care 37:2007–2014
52. Howes JM, Richardson VR, Smith KA et al (2012) Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diabetes Vasc Dis Res 9:216–225
53. Ferreira IA, Mocking AI, Feijge MA et al (2006) Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26:417–422
54. Hess K, Grant PJ (2011) Inflammation and thrombosis in diabetes. Thromb Haemost 105(Suppl 1):43–54
55. Watala C (2005) Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 11:2331–2365
56. Angiolillo DJ, Suryadevara S (2009) Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 23:375–388
57. Trovati M, Anfossi G (1998) Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells. Diabetologia 41:609–622
58. Ferroni P, Basili S, Falco A, Davi G (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2:1282–1291
59. Kannel WB, Neaton JD, Wentworth D et al (1986) Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. multiple risk factor intervention trial. Am Heart J 112:825–836
60. Jerums G, Panagiotopoulos S, Ekinci E, MacIsaac RJ (2015) Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials. J Hum Hypertens 29:473–477
61. Anonymous (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high–risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22
62. Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696
63. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393
64. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591
65. Li G, Zhang P, Wang J et al (2014) Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2:474–480
66. Wing RR, Bolin P, Brancati FL et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145–154
67. Turnbull FM, Abraira C, Anderson RJ et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298
68. Green JB, Bethel MA, Armstrong PW et al (2015) Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 373:232–242
69. White WB, Bakris GL, Bergenstal RM et al (2011) EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 162:620–626
70. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373:2117–2212
71. Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
72. Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
73. Gerstein HC, Miller ME, Genuth S et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818–828
74. Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
75. Anonymous (2005) Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N Engl J Med 353:2643–2653
76. Anonymous (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854–865
77. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359:1565–1576